Surterra Wellness has acquired Molecular Infusions (Mi), a Boston-based biotechnology research and development company that uses product delivery systems to improve the results of cannabis therapies.
The acquisition expands Surterra’s research and development capabilities. With Mi’s R&D expertise, Surterra is positioned as a force in the next wave of cannabis brand development, the company said in a statement.
Mi is focused on cannabinoid formulation and delivery with technology platforms in oral, inhalation, and topical cannabis formats, each designed to improve overall user experience, provide dosing control, and deliver more predictable and targeted health benefits.
“Acquiring Mi reflects Surterra’s intention to aggressively expand our global research and product development capabilities to launch our next wave of cannabis brands that meet patient and consumer needs today and in the future. We see endless opportunities in cannabis 3.0 – where innovation, global brand building, and ability to scale globally will lead the way,” said Surterra Chief Executive Officer William “Beau” Wrigley, Jr.
“Mi shares our long-term view and can execute in a big way. We welcome their world-class leadership and elite research teams who have blue-chip reputations and affiliations with top research and educational institutions. We look forward to disrupting the cannabis industry together.”
Molecular Infusions Platforms
Cannabis-infused beverages are one of the fastest growing segments in the cannabis market, and Mi has two beverage additive formats. Mi’s self-emulsifying drug delivery system (SEDDS) has a class-leading onset of less than 10 minutes. This water-soluble formulation is dispensed in a dropper bottle, is transparent and colorless, offers standardized potency at approximately 1mg per drop and provides a more predictable, customizable, and consistent experience for consumers.
Mi’s second beverage additive, a nanoprecipitate, provides an odorless, colorless, and flavorless experience. The company’s fine mist inhaler device breaks new ground in the pulmonary delivery of cannabinoids, as its format is as discrete as a typical asthma inhaler and has shown to quickly deliver cannabinoids with best efficiency into the lungs in measured, repeatable, irritation-free dosages. This patented, propellant-free technology was co-developed with Medspray, an expert in aerosolized drug delivery.
Surterra will integrate Mi’s proprietary technologies across Surterra’s multiple brands. The company did not disclose financial terms of the acquisition.
